NCT03092102View on ClinicalTrials.gov

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

May 20, 2017

Primary Completion Date

February 25, 2019

Study Completion Date

February 25, 2019

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

HEC585

HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.

Trial Locations (1)

35756

Covance Clinical Research Unit, Inc., Madison

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT03092102 - The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter